^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IAP0971

    i
    Other names: IAP0971, IAP-0971, IAP 0971
    Associations

    News

    Trials
    Company:
    SunHo BioPharma
    Drug class:
    PD1 inhibitor, IL-15 stimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=78, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    IAP0971
    over1year
    A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=140, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    IAP0971
    over1year
    IAP0971, A novel PD1/IL15 immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex (AACR 2023)
    The indications of IAP0971 include lung cancer, cervical cancer, head and neck squamous cell carcinoma, liver cancer, lymphoma, and other malignant tumors. A Phase I/IIa clinical trial to evaluate the safety, tolerability and preliminary efficacy of IAP0971 in patients with locally advanced or metastatic malignant tumors is currently on-going (NCT05396391).
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2 (Interleukin 2) • IL15 (Interleukin 15)
    |
    IAP0971
    almost2years
    Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex. (PubMed, Antib Ther)
    IAP0971 has demonstrated a favorable safety profile and potent anti-tumor activities in vivo. A Phase I/IIa clinical trial to evaluate the safety, tolerability and preliminary efficacy of IAP0971 in patients with advanced malignant tumors is on-going (NCT05396391).
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2 (Interleukin 2) • IL15 (Interleukin 15)
    |
    IAP0971
    over2years
    A Phase I/IIa Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=140, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    IAP0971